Objective: The objective of this consensus is to update the recommendations for the treatment of hand, hip, and knee osteoarthritis (OA) by agreeing on key propositions relating to the management of hand, hip, and knee OA, by identifying and critically appraising research evidence for the effectiveness of the treatments and by generating recommendations based on a combination of the available evidence and expert opinion of 18 countries of America.
O steoarthritis (OA) is the most common type of rheumatic disease; it is one of the main reasons for presentation to a rheumatologist. As the second most common cause of work disability after cardiovascular disease, OA incurs direct and indirect costs that have a major impact on the world economy and health systems. 1, 2 The reported prevalence of OA ranges from 0.5 to 40% of the general population. The wide variation is attributed to the variability of the clinical features of the disease and the different criteria used for diagnosis. 1, 2 Multiple patient factors are associated with an increased risk of OA, with age being the most important, followed by gender, body mass index, and microtraumas. [3] [4] [5] [6] This consensus derives from a previous study of Demographic and Clinical Characteristics of 3040 Patients by the PANLAR OA study group, reporting significant differences in handling these patients and the need for reaching an agreement in the management of OA in Latin America, taking into account the conditions of this region. 7 As there is a lack of standardized criteria for the treatment of OA, the objective of this committee of experts was to obtain agreement on OA treatment and to provide recommendations for the three most common joints affected by OA: the hand, hip, and knee.
METHODS

Literature Research
A group specialized in literature research performed a review of the literature available from 2008 to 2014 in MEDLINE, PubMed (National Center for Biotechnology Information, Bethesda, MD, USA), Cochrane Library (John Wiley & Sons, Inc., NJ, USA), and Embase (Elsevier, Madrid, Spain). The level of evidence and strength of recommendation were evaluated as shown in Table 1 , which were proposed and fully consented within the committee based on The American Heart Association EvidenceBased Scoring System. 8 A total of 896 articles were selected for analysis. The articles were classified according to the model proposed by the Center for Evidence-Based Medicine at Oxford, UK or the Jadad scale. 9 Using these criteria, 108 articles were selected, and individual responses to questions developed through the analysis of the evidence available in the literature were given by the committee of experts.
1-136
Participants
Forty-eight experts in the field of OA (rheumatologists, orthopedic surgeons, and physical medicine specialties and OA patients and a general coordinator) representing 18 Latin American countries agreed to take part in this study.
Experts' Consensus
Two sessions were conducted with the aim of reaching agreement on the final recommendations for OA in all three joints. Each participant was asked to contribute independently with questions related to key clinical aspects in the management of hand, hip, and knee OA. The consensus was reached by using a variation of the Delphi technique. The experts answered questionnaires in three rounds. After each round, a facilitator provided an anonymous summary of the experts' forecasts from the previous round and the reasons they provided for their judgments. The experts revised their earlier answers in light of the replies of other members of their panel.
Upon completion of the expert opinions, the document was edited by the Editorial Committee with the final texts approved by members of the working groups.
Recommendations for Hand OA
The recommendations for the management of hand OA are summarized in Table 2 together with the level of evidence supporting them. The treatment propositions are categorized into nonpharmacological, pharmacological, and surgical treatment modalities.
The treatment of hand OA should be individualized according to the type of OA (nodal or erosive), its location and severity, the presence of inflammation, the pain level, the level of disability and reduction in quality of life, the comorbidities and concomitant medication, and the needs and expectations of patients.
10-15
Nonpharmacological Treatment Modalities
Education with regard to joint protection should be provided (how to avoid adverse mechanical factors) together with an exercise regimen that includes muscle strengthening and range-of-motion exercises (IC). [14] [15] [16] [17] Furthermore, the combination of an orthosis (splint) with an exercise regimen to improve pain and functionality in the short and long term and an exercise regimen has been shown to decrease pain and increase the range of motion and strength in hand OA. 10, 14, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] 
Pharmacological Treatment Modalities
Pharmacological modalities of treatment include the use of topical NSAIDs, acetaminophen/paracetamol, and oral NSAIDs. Topical NSAIDs are indicated as being effective and safe for mild to moderate pain, and they are also indicated in elderly patients 
Surgical Treatment Modalities
Surgery (trapeziectomia, arthroplasty with ligament reconstruction and tendon interposition, or arthrodesis) may be considered for severe OA of the base of the first finger (rhizarthrosis) in patients who have severe pain and/or disability and after conservative treatment has failed (IIbB).
53-60 Proper use of arthroplasty or arthrodesis for the affected joints requires careful consideration of the needs of the patient with regard to the affected fingers. [55] [56] [57] [58] [59] [60] Recommendations for Hip OA
The recommendations for the management of hip OA are summarized in Table 3 together with the level of evidence supporting them. The treatment propositions are categorized into nonpharmacological, pharmacological, and surgical treatment modalities.
Nonpharmacological Treatment Modalities
Early rehabilitation is indicated to maintain mobility and prevent impairment of the extension and abduction function of the hip. Patients with hip OA should receive information and education regarding the therapeutic objectives and the importance of changes in lifestyle, which include an exercise regimen, weight reduction, the use of walking aids (walking stick and crutches) and shoe adjustments, and other measures to prevent the progression of joint damage. [62] [63] [64] Available treatment options for pain relief in patients with hip OA include thermotherapy and transcutaneous electrical nerve stimulation (TENS).
Pharmacological Treatment Modalities
The use of acetaminophen/paracetamol is recommended for use in hip OA owing to its safety profile. 65 NSAIDs may be indicated at higher than usual doses to treat more severe pain. 61, 66, 67 The use of hyaluronic acid in the treatment of hip OA may be beneficial and, thus, could help to reduce NSAID use. 70 In patients who suffer painful relapses and who do not respond to analgesics and NSAIDs, intra-articular corticosteroid injection (ultrasoundguided) may be beneficial to provide fast pain relief (IIaB).
69,70
Surgical Treatment Modalities
The recommendations for the surgical treatment of hip OA are based on the available literature from the last 2 years.
Total hip arthroplasty is a surgical modality that is undergoing continuous development. It is indicated in patients who have OA accompanied by pain and difficulty walking and whose quality of life is impaired as it improves not only these factors but also patient survival. 76 Avariety of models and metal implants are available, and different approaches can be chosen such as the use of a cemented, uncemented, or hybrid prosthesis. The available evidence shows that cemented prostheses are as effective as uncemented, 
Level of Evidence
Nonpharmacological treatment modalities 1. Education with regard to joint protection together with an exercise regimen including muscle strengthening and range of motion exercises. [14] [15] [16] [17] (IC)
2. The combination of an orthosis (splint) with an exercise regimen to improve pain and functionality in the short and long term. 7, 14, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] (IIaB)
Pharmacological treatment modalities 3. Topical NSAIDs are indicated as being effective and safe for mild to moderate pain in patients with few affected joints and in elderly patients with mild to moderate persistent pain. 13, [30] [31] [32] [33] [34] (IA)
4. Acetaminophen/paracetamol (up to 3 g/day) is the preferred oral analgesic for the long-term treatment particularly in elderly patients because of its relative safety in comparison with NSAIDs. 31, 32 (IB)
5. Oral NSAIDs are recommended at the lowest effective dose and for the shortest time possible if patients present inadequate response to acetaminophen/paracetamol. 13, 31, [35] [36] [37] The high risk associated with gastrointestinal and cardiovascular events should be considered.
(IA)
6. The use of chondroitin sulfate for pain relief and function is recommended as it has a good safety profile. [38] [39] [40] (IA) 7. Glucosamine and chondroitin sulfate are supported in the treatment of hand and knee OA. 39 (IB) 8. Steroids or intra-articular hyaluronic acid may be considered for use in the treatment of OA of the symptomatic TMC joint. 28, 29, 41 (IIaB) 9. Intramuscular steroid is not recommended for patients with symptomatic hand OA. 48 (IIIC) 10. The use of diacerein is not recommended as its effectiveness and the risk/benefits profile has not been established.
(IIIC) 11. Adalimumab or infliximab are not recommended in patients with secondary or erosive hand. 29 (IIbB) especially in the stem (femoral component), whereas uncemented prostheses are more effective for the cup (acetabular component).
Recommendations for Knee OA
The recommendations for the management of knee OA are summarized in Table 4 together with the level of evidence supporting them. The treatment propositions are categorized into nonpharmacological, pharmacological, and surgical treatment modalities.
Nonpharmacological Treatment Modalities
Information and education regarding treatment goals and the importance of lifestyle changes to reduce the degenerative damage of the knee joint should be provided to the patient. Use of support devices such as insoles and knee braces may help to reduce pain and stiffness.
61,81
Pharmacological Treatment Modalities
A wide range of pharmacological treatment modalities is available for patients with knee OA, including acetaminophen/ paracetamol, oral and topical NSAIDs, and tramadol. Furthermore, oral administration of hyaluronic acid may have a beneficial therapeutic effect in patients with symptomatic knee OA and may possibly have an even greater effect in relatively young patients. 82 Treatment with chondroitin sulfate, which has a high safety profile, has been shown to have a beneficial effect on symptoms in patients with knee OA. In addition, it has been proven that this effect persists for 3 months after stopping the treatment (carryover effect). Recent studies have provided evidence that chondroitin sulfate use may delay OA progression. 39, [83] [84] [85] Moreover, the combined use of glucosamine and chondroitin sulfate is indicated in patients with knee OA and moderate to severe pain. [98] [99] [100] Many other pharmacological treatment modalities are described in Table 4 (available only online only at…).
Surgical Treatment Modalities
Total knee arthroplasty may be indicated in the treatment of knee OA owing to its outstanding effect on pain and stiffness and the improvement obtained in physical activity 6 months after intervention. 129, 130 In patients with a partial rupture of the meniscus, a partial meniscectomy performed arthroscopically may be beneficial, followed by a physical therapy program.
131,132
DISCUSSION
From the results of a recently published study 7 of the PANLAR OA group, we found it important to have a consensus 
3. The use of orthoses is recommended to prevent the progression of degenerative changes and improve hip function. 61, 62, 64 (IIbB) 4. Thermotherapy can be performed to relieve pain. 61, 62, 64 (IB) 5. Transcutaneous electrical nerve stimulation (TENS) should also be used for pain relief and to reduce stiffness. 62 (IIbB) 6. Aerobic exercise performed on a regular basis and muscle stretching and strengthening and joint mobility exercises are recommended.
(IB)
7. The use of a walking stick in the contralateral hand is also recommended. The handle should be at the level of the greater trochanter of the femur.
(IIbB)
8. A neuromuscular bandage may be beneficial as it aids analgesia, stimulates circulation, and reduces pressure. Consequently, the patient's posture is improved.
(IIaB)
Pharmacological treatment modalities 9. The use of acetaminophen/paracetamol is recommended in mild to moderate pain, owing to its safety profile.
63
(IB) 10. NSAIDs (ibuprofen, naproxen, diclofenac, meloxicam) or selective COX-2 inhibitors (celecoxib, etoricoxib) may be indicated higher than usual doses in more severe pain. 61, 66, 67 (IB)
11. Naproxen could be used in patients with cardiovascular risk. It should be administered in conjunction with a proton-pump inhibitor owing to the high gastrointestinal risk. 13. The use of hyaluronic acid may be beneficial and, thus, could help to reduce the NSAID use.
68
(IIbB) 14. Intra-articular corticosteroid injection (ultrasound-guided) may be beneficial to provide fast pain relief in patients who suffer painful relapses and who do not respond to analgesics and NSAIDs. 69, 70 (IIaB) 15 . Avocado and soybean unsaponifiable may play a useful role, and recent studies have provided the evidence that they may slow the progression of OA.
(IIA)
16. The use of diacerein has reported a high rate of adverse effects, such as diarrhea and risk of liver damage. 49, 70 (IIIB) Surgical treatment modalities 17. Total hip arthroplasty is indicated when OA is accompanied by pain and walking difficulty and when the quality of life is impaired. It improves not only these factors but also patient survival. 74 A variety of models and metal implants are available and different approaches can be chosen such as the use of a cemented, uncemented, or hybrid prosthesis.
(IA) 
2. Hydrotherapy in a therapeutic tank may be indicated in mild knee pain without swelling or stiffness; it is especially beneficial for elderly patients. 68 A program of exercises for flexibility, mobilization, and stretching can be included. 10. Support devices may be useful for reducing pain and stiffness and improving the functionality of the knee. 79 Insoles and knee braces have been shown to decrease valgus or varus and knee pain.
(IIaA)
11. The use of bandage tape may help to reduce pain in patients with joint instability knee OA. 81 (IIaB) 12. The use of assistive devices such as a walking stick, walker, or crutches is suggested as a preventive measure.
A walking stick must be used in the contralateral hand and the height must be adjusted to the level of the greater trochanter, with the elbow bent at an angle of 25 to 30 degrees.
(IIaB)
Pharmacological treatment modalities 13. Acetaminophen/paracetamol is recommended at a dose of up to 3 g/day for the treatment of mild pain resulting from knee OA. Moderate gastrolesive effects may occur and patients should be monitored for possible hepatic complications. 63, 88 (IB)
14. NSAIDs such as diclofenac, ibuprofen, and naproxen, and selective NSAIDs including celecoxib and etoricoxib are indicated in moderate pain. 89, 90 In all cases, gastric protection, such as a proton-pump inhibitor, is required 91 and naproxen is recommended in patients with cardiovascular risk.
92
15. Topical NSAIDs may be indicated in patients with gastrointestinal risk, even though the analgesic response decreases after 1 year of use. [93] [94] [95] (IA)
16. The use of tramadol in the case of severe pain in its various administration forms is recommended.
115
(IA) 17. Capsaicin gel was shown to be an effective treatment for knee OA accompanied by mild to moderate pain. 96 (IIB) 18. Intra-articular corticosteroid injection (ultrasound-guided) may be beneficial to provide fast pain relief. 69, 70 (IIaB) 19. Chondroitin sulfate has shown to have a beneficial effect on symptoms in patients with knee OA and a high safety profile.
It has been proven that its effect persists for 3 months after stopping the treatment (carryover effect). Recent studies have provided evidence that chondroitin sulfate use may delay OA progression. 39, [83] [84] [85] [86] [87] (IA)
20. The combined use of glucosamine and chondroitin sulfate is indicated in patients with knee OA and moderate to severe pain. [97] [98] [99] [100] (IA)
21. Glucosamine may be beneficial for pain relief and for improving joint function in patients. 103 (IA) 22. Avocado soybean unsaponifiable may help to slow the progression of joint damage associated with knee OA. 71 (IIbA) 23. The administration of intra-articular steroids may be reasonable for knee OA accompanied by inflammation. 102 (IIbB) 24. Intra-articular injection of hyaluronic acid of different molecular weights has proven to be beneficial in the treatment of knee OA. 103, 104 (IIaB)
25. Oral administration of hyaluronic acid may have a beneficial therapeutic effect in patients with symptomatic knee OA and may possibly have an even greater effect in relatively young patients.
82
(IIbC)
26. The use of strontium ranelate may be beneficial for the treatment of knee pain. [105] [106] [107] (IIbB) 27. Duloxetine may be helpful for knee OA accompanied by chronic pain. 108, 109 (IIbC) 28. The administration of low-dose oral steroids for a maximum of 12 weeks could be considered in patients older than 65 years.
110
29. Intra-articular injection of platelet-rich plasma may help to relieve pain associated with knee OA [111] [112] [113] [114] [115] [116] [117] ; however, our recommendation is to conduct better quality studies.
(IIbC) 30 . The use of a supplement containing omega-3 and omega-6 fatty acids, zinc and vitamin E could be considered to reduce pain and stiffness and improve joint function, and also to reduce the intake of NSAIDs/analgesics. 124 (IIbB) on the treatment of hand, hip, and knee OA that could fit the needs of patients and specialists in America because of the significant differences in handling these patients. Moreover, the need to ensure proper care with the least economic impact, in a region in which many countries have large gaps in financial resources, and there is an important clinical diversity and various educational and cultural levels, suggests specific adaptation to regional characteristics. These recommendations for the management of patients with hand, hip, and knee OA are based on the best available evidence of benefit, safety, and tolerability of nonpharmacologic and pharmacologic and surgical treatment modalities and the consensus judgment of clinical experts from a wide range of disciplines balancing the benefits and harms of these treatments and incorporating their preferences and values.
Differences With Regard to ACR, OARSI, and EULAR
Although there are other consensus and guidelines 13, 61, 62, 79 on the treatment of OA in the mentioned locations, this consensus focused on updating the information of the available modalities with the participation of the OA specialist and patients of 18 countries of America.
CONCLUSIONS
These recommendations are based on the consensus opinions of clinical experts from a wide range of disciplines taking available evidence into account while balancing the benefits and risks of nonpharmacological, pharmacological, and surgical treatment modalities, and incorporating their preferences and values. It is hoped that these recommendations will be utilized by healthcare providers involved in the management of patients with hand, hip, and knee OA.
The pharmacological management of OA has traditionally been centered on analgesics and NSAIDs; however, increasing toxicity warnings have been issued recently for paracetamol, traditional NSAIDs, and COX-2 inhibitors, making OA chronic treatment even more challenging. The value and therapeutic efficacy of these agents are unquestionable, but there is growing awareness that they should be used for short time periods and for specific flares of the disease. The use of safer alternatives suitable for long-term administration, such as chondroitin and glucosamine, is advisable and presents growing evidence of efficacy and safety, making them a suitable alternative for long-term control of the disease. On the other hand, the use of nonpharmacological treatments should also be taken into account due to the improvements that these may produce to the quality of life of the patient. Latin America is formed by different countries with background not similar to the European or North American countries in terms of patient education or drug availability. How conditions in different regions of Latin America will need consideration. 
(IIIC)
Surgical treatment modalities 32. There is no benefit associated with the use of arthroscopy in the treatment of knee OA, even in the presence of a partial meniscal tear. 133 (IIIA) 33 . In patients with a partial rupture of the meniscus, a partial meniscectomy performed arthroscopically may be beneficial, followed by a physical therapy program. 131, 132 (IIaB) 34 . Total knee arthroplasty may be indicated owing to its outstanding effect on pain and stiffness and the improvement obtained in physical activity 6 months after intervention. 128, 129 Proper preoperative planning is essential so that deformities (varus or valgus) and long-term instabilities may be corrected.
(IIaB)
